US-based digital medicine producer Proteus Digital Health closed the second tranche of its series G round at $172m yesterday, raising the funds from undisclosed strategic investors.
Proteus reaches the first close of $120m in June. It has now raised more than $300m in funding since it was founded in 2001, and previous backers include computing company Oracle, pharmaceutical firms Otsuka and Novartis, medical device producers Medtronic and St. Jude Medical, Japan-based conglomerate Itochu, managed care provider Kaiser Permanente and semiconductor manufacturer ON.
Proteus provides a variety of products, services and data systems centred on the integration of medicine with mobile and wearable cloud computing technology.
The company intends to invest the cash, which came from investors in the US, Europe and Asia, in advancing the manufacturing and commercialisation of its digital medicine products.
Andrew Thompson, CEO of Proteus Digital Health, said: “The digital health market is rapidly forming. Investor confidence in Proteus is driven by customer excitement, our superior board and leadership team and a unique technology platform that enables us to link one of the most valuable industries of the 20th century – pharmaceuticals – to the most important utility of the 21st: the mobile internet.”